NCT03655756View on ClinicalTrials.gov

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

July 10, 2020

Study Completion Date

November 30, 2020

Conditions
Cutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IV
Interventions
BIOLOGICAL

IFx-Hu2.0

Subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

lead

TuHURA Biosciences, Inc.

INDUSTRY

NCT03655756 - pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | Biotech Hunter | Biotech Hunter